Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 231-242

  Ryan, David P ^a   Supko, Jeffrey G ^a   Eder, J Paul ^b   Seiden, Michael V ^a   Demetri, George ^b   Lynch, Thomas J ^a   Fischman, Alan J ^a   Davis, John ^a   Jimeno, Jose ^c   Clark, Jeffrey W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TRABECTEDIN;

ADULT; AGED; ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; COVALENT BOND; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; LIVER TOXICITY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; LIVER; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; TETRAHYDROISOQUINOLINES; TIME FACTORS; TOXICITY TESTS;

EID: 0035127175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
2. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
3. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo
4. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity
5. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate ecteinascidia turbinata
6. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
7. Enantioselective total synthesis of ecteinascidin 743
8. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
9. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
10. High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small cell lung, and ovarian cancer
11. Synthesis, conformation, crystal structures, and DNA cleavage abilities of tetracyclic analogs of quinocarcin
12. Antitumor antibiotics
13. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
14. NMR-based model of an ecteinascidin 743-DNA adduct
15. Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2
16. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
17. Characterization of antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743, isohomohalichondrin-B, and LL-15
18. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove
19. The antitumor agent ecteinascidin 743 (ET743) inhibits transcriptional activation of the MDRI gene by multiple inducers
20. New drugs of marine origin
21. In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)
22. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766), against human tumors explanted from patients
23. Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a 1-hour infusion every 21 days
24. Final results of a Phase I study of eceteinascidin-743 24-hour continuous infusion in advanced solid tumors patients
25. Final results of a Phase I and pharmacokinetic study of the marine minor groove binder ET-743 on a daily ×5 schedule
26. A Phase I and pharmacokinetic study of ET-743 evaluating a 3-hour intravenous infusion in patients with solid tumors
27. DC-52, a novel antitumor antibiotic. II. Isolation, physico-chemical characteristics, and structure determination
28. A Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion
29. Symbols in pharmacokinetics
30. Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters
31. The jacknife - A review
32. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
33. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies
34. maxmodel with truncated data typical of clinical studies?
35. Toxicity of Ecteinascidin 743 in female Fischer-344 rats administered i.v. in multiple-dose regimen
36. Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction
37. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
38. LC/MS analysis of ecteinascidin-743 and pharmacokinetic studies during a Phase I trial of a 72-hour continuous i.v. infusion schedule in cancer patients
39. Pharmacokinetics/pharmacodynamic relationships in patients treated with ecteinascidin-743 given as a 24-hour continuous infusion
40. Pharmacokinetics and pharmacodynamics of ET-743 in Phase I trials
41. Cytochrome P450 catalyzed metabolism of ecteinascidin 743 by rat and human liver microsomes
42. Characterization of the in vitro metabolism, pharmacokinetics, and biliary excretion of ecteinascidin 743 (NSC 648766) in male and female rats
43. Ecteinascidin-743 (ET-743) in heavily pretreated refractory sarcomas: Early results of the French experience
44. Phase I clinical and pharmacokinetic study of ecteinascidin-743 given as a 1-hour infusion every, 21 days
45. Exploratory evaluation of the potential predictors for dose-limiting toxicities in patients treated with ecteinascidin-743 (ET-743) as a 24-hour intravenous infusion every 3 weeks and its relationship to pharmacokinetics